Investing in tools to help improve the development of future therapeutics

Measuring disease progression and the impact of therapeutic candidates in Duchenne muscular dystrophy (Duchenne) is especially difficult because of its complexity. Investing time and effort into better understanding disease biology and measurable changes that correlate with the disease state can help us accelerate the discovery and development of meaningful treatments.

At Solid, we are focused on developing biomarkers and sensors that will allow us to identify treatment targets more efficiently, better measure the potential efficacy of product candidates and reach therapeutic decision points faster.

These tools include:

• Blood-based and imaging biomarkers to reduce the need for muscle biopsies in the clinic
• Sensor-less mobility tracking to better understand naturalistic motor function